Although statins have proven efficacy in lowering lipids and improving survival in heart transplantation (HT) recipients, potential drug interactions may limit efficacy and reduce tolerability. This observational study explored the efficacy and tolerability of ezetimibe (10 mg/day) combined with simvastatin (10 or 20 mg/day) prescribed to HT recipients with intolerance to statins (n = 11) or inadequate lipid control despite high-dose statins (n = 14). Substantial reductions in lipid levels were apparent after 2 months (total cholesterol, -22%; low-density lipoproteins, -28%; triglycerides, -31%) and were maintained at 6 months. Reductions were significant in both subgroups of recipients; the vast majority (12 of 14, 85%) of recipients with a history of statins intolerance were able to tolerate ezetimibe plus low-dose simvastatin. This study provides suggestive evidence that treatment with ezetimibe plus low-dose simvastatin is well tolerated by HT recipients and may be effective for treatment of dyslipidemia in HT recipients with statins intolerance or resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healun.2008.02.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Outcomes in Heart Transplantation: The Role of High-Intensity Statin Therapy.
J Biochem Mol Toxicol
December 2024
Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Heart transplantation is a vital procedure for patients with end-stage heart failure, but it faces significant challenges, including graft dysfunction, rejection, and cardiac allograft vasculopathy (CAV), which can compromise long-term graft success. Research suggests that statin therapy may offer significant benefits to heart transplant recipients, such as improved long-term survival and reduced rates of graft rejection and mortality. The aim of this review is to thoroughly examine the recent literature on this topic since 2005.
View Article and Find Full Text PDFA Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi-ancestry population from the Million Veteran Program.
Alcohol Clin Exp Res (Hoboken)
December 2024
Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Article Synopsis
Burden of atherogenic lipids and association with cardiac allograft vasculopathy in heart transplant recipients.
J Clin Lipidol
November 2024
Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address:
Background: Cardiac Allograft Vasculopathy (CAV) is a leading cause of morbidity and mortality after heart transplantation. There are limited contemporary studies examining post-transplant lipid management and cardiometabolic health.
Objective: We study the burden of cardiometabolic derangements post transplantation and its impact on CAV in a modern cohort of heart transplant recipients.
Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation.
Transplant Proc
November 2024
Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China. Electronic address:
Objective: To assess the impact of long-term atorvastatin (ATO) therapy on reducing recipient inflammation and immune response, thus lowering the risk of chronic lung allograft dysfunction (CLAD) in lung transplant recipients. This study aimed to investigate the effects of ATO on overall survival, lung function recovery, and its influence on inflammatory factors alongside azithromycin (AZI) prophylaxis.
Methods: This retrospective single-center study included lung transplant recipients from January 2017 to December 2022.
The Korean Organ Transplant Registry (KOTRY): Third Official Adult Heart Transplant Report.
Korean Circ J
October 2024
Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Background And Objectives: The Korean Organ Transplant Registry (KOTRY) provided data for this third official report on adult heart transplantation (HT), including information from 709 recipients.
Methods: Data from HTs performed at seven major centers in Korea between March 2014 and December 2020 were analyzed, focusing on immunosuppression, acute rejection, cardiac allograft vasculopathy (CAV), post-transplant survival, and mechanical circulatory support (MCS) usage.
Results: The median ages of the recipients and donors were 56.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!